Company Overview
About InpharmD
InpharmD is an Atlanta-based healthcare technology company providing AI-assisted drug information and clinical pharmacist intelligence to healthcare providers — enabling physicians, nurses, and clinical staff to get evidence-based answers to complex drug questions (drug interactions, off-label use guidance, dosing in special populations, emerging therapies) through an AI platform that combines clinical pharmacist review with database-backed pharmaceutical intelligence. Founded in 2018 and a Y Combinator W21 graduate, InpharmD raised $6.63 million total including a $6.5 million seed round in December 2023 led by 645 Ventures with participation from Qlarant Capital and Atlanta Ventures.
Business Model & Competitive Advantage
InpharmD's platform delivers AI-generated drug information responses that are reviewed and validated by clinical pharmacists before delivery, providing a higher standard of reliability than pure AI-generated responses for clinical decision support. Healthcare providers can query drug interactions for complex polypharmacy patients, dosing guidance for renal or hepatic impairment, and evidence reviews for emerging treatments where prescribing guidance is evolving rapidly. The pharmacist-in-the-loop review model addresses the reliability requirements for clinical AI tools where incorrect information can cause patient harm.
Competitive Landscape 2025–2026
In 2025, InpharmD competes in the clinical decision support and pharmacy intelligence market with Wolters Kluwer (UpToDate, the dominant clinical reference), Elsevier (Clinical Pharmacology), IBM Watson Health (legacy), and newer AI clinical assistants (Doximity AI, Glass Health) for healthcare provider drug information. Clinical pharmacist access is increasingly limited in many hospital systems — telepharmacy and centralized pharmacy models have reduced the availability of pharmacists for individual clinician questions. InpharmD's AI-assisted pharmacist service expands access to pharmaceutical expertise. The 645 Ventures and YC backing validates the healthcare AI market opportunity. The 2025 strategy focuses on hospital system and health system enterprise deployments, expanding the AI model's pharmaceutical knowledge base, and building the formulary and insurance coverage intelligence that completes the prescribing decision context.
Recent Activity
View all →Foreign Filing filed 2026-05-07
Foreign Filing filed 2026-05-07
Foreign Filing filed 2026-04-16
Foreign Filing filed 2026-04-02
Annual Report (foreign) filed 2026-04-02
Foreign Filing filed 2026-03-27
Foreign Filing filed 2026-03-24
Key Differentiators
Emerging Innovator
InpharmD is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare InpharmD with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from InpharmD? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim InpharmD Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention InpharmD vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →